Brokerages expect that Pluristem Therapeutics Inc. (NASDAQ:PSTI) will report earnings of ($0.80) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Pluristem Therapeutics’ earnings. Pluristem Therapeutics also reported earnings per share of ($0.80) during the same quarter last year. The firm is scheduled to announce its next earnings results on Thursday, November 14th.
According to Zacks, analysts expect that Pluristem Therapeutics will report full-year earnings of ($2.49) per share for the current fiscal year, with EPS estimates ranging from ($2.90) to ($2.08). For the next year, analysts expect that the business will post earnings of ($1.80) per share. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Pluristem Therapeutics.
A number of equities analysts recently issued reports on PSTI shares. ValuEngine downgraded Pluristem Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. LADENBURG THALM/SH SH started coverage on Pluristem Therapeutics in a report on Monday, July 22nd. They issued a “buy” rating for the company. Finally, Zacks Investment Research raised Pluristem Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 10th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Pluristem Therapeutics presently has an average rating of “Buy” and a consensus price target of $27.50.
Shares of NASDAQ PSTI traded up $0.05 during midday trading on Wednesday, hitting $3.68. 16,700 shares of the company’s stock were exchanged, compared to its average volume of 54,355. Pluristem Therapeutics has a twelve month low of $3.24 and a twelve month high of $12.50. The company has a market cap of $57.22 million, a PE ratio of -1.47 and a beta of 1.05. The firm’s fifty day simple moving average is $3.90 and its 200-day simple moving average is $1.97.
About Pluristem Therapeutics
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Recommended Story: What is cost of equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.